TCR-NK-X / Karolinska Institute, Zelluna - LARVOL DELTA

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Zelluna Immunotherapy AS

New P1 trial • Head and Neck Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Synovial Sarcoma • MAGEA4

A novel ‘off the shelf’ TCR-NK cell therapy platform for the treatment of solid tumours: development of optimised MAGE-A4 targeting TCR-NK cells for advancement into the clinic (SITC 2023) - "Conclusions Taken together, these data demonstrate the feasibility and potential of generating optimised TCR-NK cells from PB-NK resulting in a highly potent cell product combining TCR-mediated and innate NK killing functions. Based on the potency and safety profile, ZI-MA4–1 has advanced into manufacturing with a preclinical package underway to enable a clinical trial for treatment of patients with advanced solid tumours."

IO biomarker • Oncology • Solid Tumor • CD8 • MAGEA4

Zelluna Immunotherapy announces a collaboration with Lion TCR to develop allogeneic “off-the-shelf” TCR based Natural Killer (TCR-NK) cell therapies for the treatment of virally induced cancers (PharmiWeb) - "Zelluna Immunotherapy...announces a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers. Under the collaboration the parties will leverage Zelluna’s proprietary TCR-NK platform and TCR translational experience...The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options."

Licensing / partnership • Oncology